in addition, a wireless carrier must implement E911 service within the six-month period following the date of the PSAP's request. If the carrier challenges the validity of the request, the request will be deemed valid if the PSAP making the request provides the following information:

(a) Cost Recovery: The PSAP must demonstrate that a mechanism is in place by which the PSAP will recover its costs of the facilities and equipment necessary to receive and utilize the E911 data elements.

(b) Necessary Equipment: The PSAP must provide evidence that it has ordered the equipment necessary to receive and utilize the E911 data elements; and

(c) Necessary Facilities: The PSAP must demonstrate that it has made a timely request to the appropriate local exchange carrier (LEC) for the necessary trunking and other facilities to enable E911 data to be transmitted to the PSAP.

This collection is needed to ensure that they are ready to receive E911 Phase I or Phase II information at the time that wireless carrier’s obligation to deliver that information becomes due. This will reduce the possibility of both carriers and PSAPs investing money that they are ready to receive E911 data to be transmitted to the PSAP.

The Commission revised this information collection to add questions about prefill applications and the number of available channels; and to make clarifications for some existing questions to the on-line database screens. This is being done to make completion of the form easier for the respondents.

Federal Communications Commission.

Marlene H. Dortch,
Secretary, Office of the Secretary, Office of Managing Director.

[FR Doc. 2012–75 Filed 1–6–12; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL ELECTION COMMISSION

Sunshine Act Notice

AGENCY: Federal Election Commission.

DATES: Date and Time: Thursday, January 12, 2012 at 10 a.m.

PLACE: 999 E Street NW., Washington, DC (Ninth Floor)

STATUS: This Meeting will be Open to the Public.

ITEMS TO BE DISCUSSED:

Correction and Approval of the Minutes for the Meeting of December 15, 2011.


Management and Administrative Matters.

Individuals who plan to attend and require special assistance, such as sign language interpretation or other reasonable accommodations, should contact Shelley E. Garr, Deputy Secretary, at (202) 694–1040, at least 72 hours prior to the hearing date.

PERSON TO CONTACT FOR INFORMATION: Judith Ingram, Press Officer, Telephone: (202) 694–1220.

Shelley E. Garr,
Deputy Secretary of the Commission.

[FR Doc. 2012–127 Filed 1–6–12; 8:45 am]

BILLING CODE 6715–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the National Biodefense Science Board

AGENCY: Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the National Biodefense Science Board (NBSB) will be holding a public meeting, followed by a closed portion of the meeting under exemption 9(B) of the Government in Sunshine Act, 5 U.S.C. 552b(c).

DATES: The February 2, 2012 NBSB public meeting is tentatively scheduled.
from 10:30 a.m. to 12:30 p.m. A portion of the public meeting will be closed and is tentatively scheduled from 2 p.m. to 5 p.m. The agenda is subject to change as priorities dictate. Please check the NBSB Web site for the most up-to-date information on the meeting.

ADDITIONS: Omni Shoreham Hotel, Palladian Ballroom, 2500 Calvert Street NW. (at Connecticut Ave.) Washington, District of Columbia 20008. To attend by teleconference, call 1–(866) 395–4129, pass-code “ASPR.” Please call 15 minutes prior to the beginning of the conference call to facilitate attendance. Pre-registration is required for in person attendance. Individuals who wish to attend the meeting in person should send an email to NBSB@HHS.GOV with “NBSB Registration” in the subject line.

FOR FURTHER INFORMATION CONTACT:
MacKenzie Robertson, Acting Executive Director, NBSB, Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services; (202) 260–0447; fax (202) 205–8508; Email: NBSB@HHS.GOV.

SUPPLEMENTARY INFORMATION: Pursuant to section 319M of the Public Health Service Act (42 U.S.C. 247d–7f) and section 222 of the Public Health Service Act (42 U.S.C. 217a), the Department of Health and Human Services established the National Biodefense Science Board. The Board shall provide expert advice and guidance to the Secretary on scientific, technical, and other matters of special interest to the Department of Health and Human Services regarding current and future chemical, biological, nuclear, and radiological agents, whether naturally occurring, accidental, or deliberate. The Board may also provide advice and guidance to the Secretary and/or the Assistant Secretary for Preparedness and Response on other matters related to public health emergency preparedness and response.

Background: A portion of this public meeting will be dedicated to swearing in the seven new voting members who will replace the members whose 4-year terms will expire on January 31, 2012. The Board will also be asked to review and evaluate the 2012 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan (SIP). Until a final document is approved by the Secretary of the Department of Health and Human Services (HHS), the development of PHEMCE SIP requires consideration and discussion of procurement-sensitive information that should not be released to the public prior to the Secretary’s final decision. Premature public disclosure of the draft PHEMCE SIP would limit the Secretary’s decision-making ability to effectively prioritize HHS expenditures on critical medical countermeasures. Therefore, the Board’s deliberations on the new task will be conducted in closed session in accordance with provisions set forth under exemption 9(B) of the Government in Sunshine Act, 5 U.S.C. section 552(b)(c), and with approval by the Assistant Secretary for Preparedness and Response.

Availability of Materials: The meeting agenda and materials will be posted on the NBSB Web site at http://www.phe.gov/Preparedness/legal/boards/nbsb/Pages/default.aspx prior to the meeting.

Procedures for Providing Public Input: Any member of the public providing oral comments at the meeting must sign in at the registration desk and provide his/her name, address, and affiliation. All written comments must be received prior to January 26, 2012 and should be sent by email to NBSB@HHS.GOV with “NBSB Public Comment” as the subject line. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should email NBSB@HHS.GOV.

Nicole Lurie, Assistant Secretary for Preparedness and Response.
[FR Doc. 2012–152 Filed 1–6–12; 8:45 am]
BILLING CODE 4150–37–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–N–0454]

Privacy Act of 1974; Report of an Altered System of Records, Including Addition of Routine Uses to an Existing System of Records; Bioresearch Monitoring Information System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of an altered system of records.

SUMMARY: The Food and Drug Administration (FDA) is announcing an alteration to an existing System of Records (System) titled “Bioresearch Monitoring Information System, HHS/FDA” (System No. 09–10–0010). Among other updates, this alteration adds new routine uses for disclosures of certain relevant information to Agencies, authorities, and organizations with responsibilities related to clinical investigations and/or clinical investigators; persons who require access to records to perform services for FDA; and individual research subjects.

DATES: This notice will be effective without further notice on February 8, 2012 unless modified by a subsequent notice making changes in response to public comments. FDA invites comments on all parts of the systems notice. Comments must be received on or before February 8, 2012. See ADDRESSES for information about submission of comments.

ADDRESSES: You may submit comments identified by Docket No. FDA–2011–N–0454 by any of the following methods:

Electronic Submissions
Submit electronic comments in the following way:
• Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments.

Written Submissions
Submit written submissions in the following ways:
• Fax: (301) 827–6870.
• Mail/Hand delivery/Courier (for paper or CD-ROM submissions): Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Instructions: All submissions received must include the Agency name and Docket No. FDA–2011–N–0454 for this notice. All comments received may be posted without change to http://www.regulations.gov, including any personal information provided. For additional information on submitting comments, see the “Comments” heading of the SUPPLEMENTARY INFORMATION section of this document.

Docket: For access to the docket to read background documents or comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:
Kathleen E. Pfaender, Office of Good Clinical Practice, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5129, Silver Spring, MD 20993–0002, (301) 796–8340.

SUPPLEMENTARY INFORMATION:
I. Background
The Bioresearch Monitoring Information System provides controls to